OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
December 13, 2023
The seminar examines where members of the pharma supply chain stand in terms of preparation, being that the act has officially been enacted.
December 12, 2023
Bayer executive talks Enable Holistic Hub and Provider Services panel.
Session discusses ways to integrate digital pharmacies and hubs.
Founding Partner of Curatio Scientia speaks on her upcoming panel at Trade & Channel Strategies 2023.
AstraZeneca's deal to acquire Icosavax is expected to bolster AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with IVX-A12, a potential first-in-class vaccine for both respiratory syncytial virus and human metapneumovirus.
Bristol Myers Squibb strikes deal with SystImmune for the rights to codevelop and sell a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate that has shown promise in non-small cell lung cancer and breast cancer.
December 11, 2023
Lexicon Pharmaceuticals exec discusses upcoming Enable Holistic Hub and Provider Services panel.
Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.
Conference keynote offers an industry outlook, including new commercialization challenges.
Phase III INTerpath-002 trial will evaluate the novel individualized neoantigen therapy V940 (mRNA-4157) with Keytruda (pembrolizumab) as an adjuvant treatment for patients with non-small cell lung cancer.